GA SB72

Expands Georgia's existing "Right to Try" law to allow patients with life-threatening or severely debilitating illnesses (not just terminal illness) to access individualized investigational treatments based on their own genetic profile, including gene therapy, antisense oligonucleotides, and neoantigen vaccines

Requires physician documentation that the patient has considered all FDA-approved options and received a treatment recommendation based on genomic analysis, along with detailed written informed consent covering risks, costs, and insurance limitations

Prohibits the Georgia Composite Medical Board from sanctioning physicians solely for recommending or prescribing these treatments, and bars the Department of Community Health from acting against providers' Medicare certification for such recommendations

Manufacturers and eligible facilities (those with Federalwide Assurance for human subjects protection) may provide treatments at cost or free, but are not required to do so; health plans may cover but are not mandated to cover these treatments

Provides liability protections for manufacturers, facilities, and physicians who comply with the law in good faith, and exempts a deceased patient's estate from remaining treatment-related debt if death was caused by the investigational treatment